|
| Status |
Public on Aug 20, 2011 |
| Title |
A Gene Expression-Based Risk Stratification Model for Newly Diagnosed Multiple Myeloma |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
We recently defined a gene expression-based signature of high-risk multiple myeloma; this predictive signature was developed with and independently validated for newly diagnosed patients treated with high dose therapy and stem cell rescue. Here we use Phase 3 clinical trial data to show that this signature also predicts short survival in relapsed disease treated with single agent bortezomib or high dose dexamethasone. In addition, a survival signature derived with relapsed myeloma samples identified newly diagnosed patients with short survival. Taken together these data suggest that a similar biology underlies poor outcome in both newly diagnosed and relapsed myeloma and provide strong evidence that the high-risk signature is a powerful tool to identify patients who are candidates for new therapeutic regimens.
Keywords: Model validation
|
| |
|
| Overall design |
See above (Series_summary)
|
| |
|
| Contributor(s) |
Shaughnessy JD Jr |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Sep 07, 2007 |
| Last update date |
Aug 10, 2018 |
| Contact name |
Yiming Zhou |
| E-mail(s) |
[email protected]
|
| Phone |
(501)296-1503 1413
|
| Organization name |
Myeloma Institute for Research and Therapy
|
| Street address |
4301 West Markham St., Slot 776
|
| City |
Little Rock |
| State/province |
AR |
| ZIP/Postal code |
72205 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL96 |
[HG-U133A] Affymetrix Human Genome U133A Array |
| GPL97 |
[HG-U133B] Affymetrix Human Genome U133B Array |
|
| Samples (288)
|
|
| Relations |
| BioProject |
PRJNA102461 |
Less...
More...